Sokpe Authentia, Mensah Merlin L K, Koffuor George A, Thomford Kwesi P, Arthur Richmond, Jibira Yakubu, Baah Michael K, Adedi Bright, Agbemenyah Hope Y
Department of Pharmacognosy, Faculty of Pharmacy and Pharmaceutical Sciences, KNUST, Kumasi, Ghana.
Department of Herbal Medicine, Faculty of Pharmacy and Pharmaceutical Sciences, KNUST, Kumasi, Ghana.
Evid Based Complement Alternat Med. 2020 Dec 10;2020:8833828. doi: 10.1155/2020/8833828. eCollection 2020.
In the management of hypertension (a cardiovascular disease and the leading metabolic risk factor in noncommunicable diseases) with herbal medicines, efficacy and safety are of uttermost concern. This study sought to establish hypotensive, antihypertensive, drug interaction, and safety for use of the aqueous leaf extracts of (AME), (PAE), or their combination products (CAPE). . Systolic and diastolic blood pressure (SBP and DBP), mean arterial blood pressure (MAP), and heart rate (HR) were measured in normotensive Sprague-Dawley rats treated with 50-150 mg/kg of AME, PAE, or CAPE to establish a hypotensive effect. "Combination index" was calculated to establish interaction between AME and PAE. The antihypertensive effect of CAPE was established by measuring SBP, DBP, MAP, and HR in ethanol-sucrose- and epinephrine-induced hypertension. Full blood count, liver and kidney function tests, and urinalysis were determined in ethanol/sucrose-induced hypertension to establish safety for use.
AME, PAE, and CAPE significantly ( ≤ 0.001) decreased BP in both normotensive and hypertensive animals. Effects of CAPE 1, CAPE 2, and CAPE 3 were synergistic (combination indices of 0.65 ± 0.07, 0.76 ± 0.09, and 0.87 ± 0.07, respectively). There was a significant decrease ( ≤ 0.01 - 0.001) in SBP and MAP with 100 mg/kg CAPE 1 and 75 mg/kg CAPE 2 treatment in hypertension as well as with nifedipine ( ≤ 0.001) treatment. Epinephrine-induced hypertension in anesthetized cats was significantly and dose-dependently inhibited ( < 0.05 - 0.001) by 25-100 mg/ml CAPE 1 and 37.5-75 mg/ml CAPE 2. CAPE administration had no deleterious effect ( > 0.05) on full blood count, liver and kidney function, and urine composition in hypertensive rats.
The aqueous leaf extracts of , and their combination products possess antihypertensive properties, with combination products showing synergism and safety with use.
在用草药治疗高血压（一种心血管疾病且是非传染性疾病中主要的代谢风险因素）时，疗效和安全性至关重要。本研究旨在确定 （AME）、 （PAE）的水叶提取物或其组合产品（CAPE）的降压、抗高血压、药物相互作用及使用安全性。在正常血压的Sprague-Dawley大鼠中，给予50 - 150mg/kg的AME、PAE或CAPE，测量收缩压和舒张压（SBP和DBP）、平均动脉压（MAP）和心率（HR），以确定其降压效果。计算“组合指数”以确定AME和PAE之间的相互作用。通过测量乙醇 - 蔗糖和肾上腺素诱导的高血压大鼠的SBP、DBP、MAP和HR来确定CAPE的抗高血压作用。在乙醇/蔗糖诱导的高血压大鼠中进行全血细胞计数、肝肾功能测试和尿液分析，以确定其使用安全性。
AME、PAE和CAPE在正常血压和高血压动物中均显著（≤0.001）降低血压。CAPE 1、CAPE 2和CAPE 3的作用具有协同性（组合指数分别为0.65±0.07、0.76±0.09和0.87±0.07）。在高血压大鼠中，100mg/kg CAPE 1和75mg/kg CAPE 2治疗以及硝苯地平（≤0.001）治疗后，SBP和MAP显著降低（≤0.01 - 0.001）。25 - 100mg/ml CAPE 1和37.5 - 75mg/ml CAPE 2可显著且剂量依赖性地抑制麻醉猫的肾上腺素诱导的高血压（<0.05 - 0.001）。给予CAPE对高血压大鼠的全血细胞计数、肝肾功能和尿液成分无有害影响（>0.05）。
及其组合产品的水叶提取物具有抗高血压特性，组合产品显示出协同作用且使用安全。
Zotero 插件
